Fig. 2

Genomic profiling using baseline tissue samples. A Mutational landscape of patients using treatment-naive tissue samples. The genomic profiles focused on individual genes with a mutation count ≥ 2, actionable genes annotated by OncoKB, and signaling pathways with a mutation count ≥ 3. B, C Bar plots showing the prevalence of gene alterations and pathways stratified by histological subtype (B) or the MCL International Prognostic Index (MIPI) (C). D, E Kaplan–Meier survival curves showing the associations between genetic alterations/pathways and progression-free survival (D) and overall survival (E). F Lollipop plot highlighting the specific ATM mutation sites identified in baseline tissue samples. G Multivariate Cox regression analysis for progression-free survival incorporating significant clinical and mutational features identified in the univariate analysis